Ella Liberzon

Ella Liberzon has held various roles in the biopharmaceutical industry since 2004. Ella began their career as a Postdoctoral Fellow at the Dana-Farber Cancer Institute in 2004. In 2010, they became a Research Specialist I at the Kaelin Laboratory of the Howard Hughes Medical Institute/ Dana Farber Cancer Institute. From 2018 to 2022, they held the roles of Senior Scientist and Scientist at TCR² Therapeutics Inc. Currently, Ella is a Principal Scientist at Be Biopharma.

Ella Liberzon obtained a Bachelor of Science (B.Sc.) from Bar-Ilan University, followed by a Master of Science (M.Sc.) from the same institution. Ella then went on to receive a Doctor of Philosophy (Ph.D.) in Genetics from Tel Aviv University.